Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3146674 | 0.92 | CHRNB4 (0.43) | FFAR4CHRNB4CHRNA3CHRNA7P2RX7 | |
| SCHEMBL3151015 | 0.91 | FFAR4 (0.40) | FFAR4CHRNB4CHRNA3CHRNA7P2RX7 | |
| SCHEMBL3147012 | 0.90 | FFAR4 (0.44) | FFAR4CHRNB4CHRNA3CHRNA7P2RX7 | |
| SCHEMBL3150641 | 0.90 | P2RX7 (0.40) | FFAR4CHRNB4CHRNA3CHRNA7P2RX7 | |
| SCHEMBL3147063 | 0.89 | P2RX7 (0.44) | FFAR4CHRNB4CHRNA3CHRNA7P2RX7 | |
| SCHEMBL3147209 | 0.88 | ABL1 (0.39) | FFAR4P2RX7EGLN1 | |
| SCHEMBL3147051 | 0.88 | FFAR4 (0.38) | FFAR4CHRNB4CHRNA3CHRNA7P2RX7 | |
| SCHEMBL3155882 | 0.88 | FFAR4 (0.36) | FFAR4EGLN1 | |
| SCHEMBL3151249 | 0.86 | FFAR4 (0.38) | FFAR4CHRNB4CHRNA3CHRNA7P2RX7 | |
| SCHEMBL3151266 | 0.86 | FFAR4 (0.38) | FFAR4CHRNB4CHRNA3CHRNA7P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317698-A1 | Polysubstituted Pyridinylaminoalkylene- and Pyridinyloxyalkylene-Cyclopropanamine Compounds, a Process for Their Preparation and Pharmaceutical Compositions Containing Them | LES LABORATOIRES SERVIER (FR) | 2010-12-16 | — | — | US | disclosed |
| EP-1979321-B9 | NOVEL PYRIDINYLAMINOALKYLENE- AND PYRIDINYLOXYALKYLENE-CYCLOPROPANAMINES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2010-02-17 | — | — | EP | disclosed |
| EP-1979321-B1 | NOVEL PYRIDINYLAMINOALKYLENE- AND PYRIDINYLOXYALKYLENE-CYCLOPROPANAMINES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2009-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317698-A1 | Polysubstituted Pyridinylaminoalkylene- and Pyridinyloxyalkylene-Cyclopropanamine Compounds, a Process for Their Preparation and Pharmaceutical Compositions Containing Them | CHRNA6, CHRNE, CHRNG | FFAR4 110/4885CHRNB4 16/4885CHRNA3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.